Clinical trial · Interventional
Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer
γδ T Cell Immunotherapy for Treatment of Hepatocellular Liver Cancer
NCT02425735CI-TRIAL-00023136completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, effects of γδT cells on human hepatocellular liver cancer in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC-CIK cells | Biological | — | UNRESOLVED |
| γδ T cells | Biological | — | UNRESOLVED |
| γδ T/DC-CIK cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group A
- description
- DC-CIK cells will be used against tumor cells.
- interventionNames
- Biological: DC-CIK cells
- type
- EXPERIMENTAL
- label
- Group B
- description
- γδ T cells will be used against tumor cells.
- interventionNames
- Biological: γδ T cells
- type
- EXPERIMENTAL
- label
- Group C
- description
- Combination of γδ T cells/ DC-CIK be used against tumor cells.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:18-75 2. Karnofsky performance status \>50 3. Diagnosis with hepatocellular carcinoma cancer based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Will receive cryosurgery, gd Tcells/ DC-CIK. 6. Life expectancy: Greater than 3 months 7. Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: 1. Patients with other kinds of cancer 2. History of coagulation disorders or anemia 3. Patients with heart disease and diabetes
References
Publications (1)
- DERIVEDAlnaggar M, Xu Y, Li J, He J, Chen J, Li M, Wu Q, Lin L, Liang Y, Wang X, Li J, Hu Y, Chen Y, Xu K, Wu Y, Yin Z. Allogenic Vgamma9Vdelta2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer. 2019 Feb 8;7(1):36. doi: 10.1186/s40425-019-0501-8. PMID 30736852